AstraZeneca Plc AZN reported updated clinical outcomes across its oncology portfolio, demonstrating sustained long-term ...

The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of ...

Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche ...

A breast cancer drug from AstraZeneca will now be available in England after a pricing deal was reached, in part a result of ...

The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

AstraZeneca (LSE:AZN) and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy. Long-term ...

A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use ...

AstraZeneca PLC and its partner Daiichi Sankyo Co Ltd on Friday announced that their cancer drug Enhertu has been recommended to be approved in the EU for a form of breast cancer. AstraZeneca, the ...

The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked ...

NEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) announces a new research collaboration with AstraZeneca aimed at driving progress in small cell lung cancer (SCLC) ...

UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its ...

Joint Cancer Research Horizon-AstraZeneca Functional Genomics Centre has the following research output in the current window (1 January 2025 - 31 December 2025) of the Nature Index. Click on Count to ...